These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 25806780)

  • 1. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
    Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
    Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
    Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
    Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.
    Ascierto PA; Simeone E; Giannarelli D; Grimaldi AM; Romano A; Mozzillo N
    J Transl Med; 2012 May; 10():107. PubMed ID: 22640478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
    Ackerman A; Klein O; McDermott DF; Wang W; Ibrahim N; Lawrence DP; Gunturi A; Flaherty KT; Hodi FS; Kefford R; Menzies AM; Atkins MB; Long GV; Sullivan RJ
    Cancer; 2014 Jun; 120(11):1695-701. PubMed ID: 24577748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.
    Ascierto PA; Vanella V; Grimaldi AM; Lucia F; Palla M; Simeone E; Mozzillo N
    Cancer Immunol Immunother; 2016 Nov; 65(11):1395-1400. PubMed ID: 27604993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
    Ascierto PA; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Cao MG; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Dummer R; Sileni VC; Palmieri G
    Nat Commun; 2024 Jan; 15(1):146. PubMed ID: 38167503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in managing metastatic melanoma: which treatment when?
    Amaral T; Meraz-Torres F; Garbe C
    Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.
    Gibney GT; Zaemes J; Shand S; Shah NJ; Swoboda D; Gardner K; Radfar A; Petronic-Rosic V; Reilly MJ; Al-Refaie WB; Rapisuwon S; Atkins MB
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261206I.
    Markovic SN; Suman VJ; Javed A; Reid JM; Wall DJ; Erickson LA; Ernstoff M; Anderson DM
    Am J Clin Oncol; 2020 Feb; 43(2):115-121. PubMed ID: 31809326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
    Menzies AM; Long GV
    Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
    Zhou AY; Johnson DB
    Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
    Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P
    Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
    Kropp LM; De Los Santos JF; McKee SB; Conry RM
    J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.